3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
16
Neoplasms
1
Multiple Endocrine Neoplasia Type 2a
1
Lung Neoplasms
1
Carcinoma, Squamous Cell
1
Carcinoma, Large Cell
1
Carcinoma
1
Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer
1
Adenocarcinoma
1
ALK-positive NSCLC
1
Interventions
Cisplatin
8
Radiotherapy
5
Paclitaxel
5
Docetaxel
5
Cetuximab
4
Carboplatin
4
pembrolizumab
3
figitumumab
2
cemiplimab
2
advexin
2
Radiation
2
Methotrexate
2
Fluorouracil
2
Drug Therapy
2
Bleomycin
2
vandetanib
1
talimogene laherparepvec
1
sintilimab
1
nedaplatin
1
nanocis
1
methyl 5-aminolevulinate
1
ficlatuzumab
1
dusquetide
1
brigatinib
1
avasopasem manganese
1
alpha-2'-deoxythioguanosine
1
Vinorelbine
1
Tretinoin
1
Tirapazamine
1
Technetium-99
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Carcinoma, Squamous Cell
×
Crizotinib
×
Clear all
NCT02737501
2021-08-20
ALTA-1L
Takeda
Phase 3
Completed
275 enrolled
23 charts
1 FDA